Stock Evaluator: Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. AVLN

$27.69 -0.23 -0.82%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 404,542
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics AVLN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,243.0 $436.9 49%
Shares Out (Mil) 44.4 46.5 44%
Institutional Ownership na 82.2% na
Float (Mil) 29.9 47.7 36%
Beta na 0.68 na
Avg Daily Volume (000s) 517 339 57%
Price Change
(52-week)
na 52.1% na
Growth AVLN Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.6% na
Net Income (5yr) na (1.6%) na
EPS (5yr) na 15.1% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (15.1%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.720) ($2.690) ($2.580)
Month Ago EPS ($0.720) ($2.690) ($2.580)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS na ($1.940) ($1.900)
Year/Year Chg 7.6% (96.9%) (96.9%)
Financials AVLN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $289 na
Net Income (TTM) (Mil) ($109) ($11) 10%
EPS (TTM) ($5.687) ($0.600) 7%
Operating Cash Flow (TTM) (Mil) ($106) ($7) 6%
Net Cash Flow (TTM) (Mil) $59 $1 72%
Long-Term Debt (Q1) (Mil) $16 $6 31%
Enterprise Value (Q1) (Mil) $978 $331 41%
Valuation AVLN Industry
Median
Percentile
(All Stocks)
P/B 3.35 2.15 72%
P/E na 24.2 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios AVLN Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.5% na
Net Margin na 3.6% na
ROA (54.8%) (23.3%) 10%
ROE (59.1%) (24.7%) 14%
Liabilities to Assets 7.3% 31.8% 4%
F-Score 1 3 na

Avalyn Pharma Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors